When should an intravenous iron infusion be offered to a pregnant woman with iron‑deficiency anemia, considering hemoglobin level, gestational age, iron studies (serum ferritin <30 ng/mL or transferrin saturation <20%), and intolerance or contraindication to oral iron?

When to Offer Intravenous Iron Infusion in Pregnancy

Intravenous iron should be offered to pregnant women with iron-deficiency anemia when oral iron has failed after 4 weeks, when oral iron is not tolerated, when hemoglobin is severely low (<9.0 g/dL), or when rapid correction is needed in the second or third trimester. 1

Diagnostic Confirmation Before IV Iron

Before considering IV iron, confirm true iron-deficiency anemia:

• Serum ferritin ≤15 μg/L in an anemic pregnant woman confirms iron deficiency with 98% specificity 2
• Hemoglobin thresholds for anemia in pregnancy are <11 g/dL in the first and third trimesters, and <10.5 g/dL in the second trimester 3
• Verify compliance with oral iron and absence of acute illness before declaring oral iron failure 1
• Consider alternative diagnoses (thalassemia, sickle cell trait) in women of African, Mediterranean, or Southeast Asian ancestry who do not respond to oral iron 1

Specific Indications for IV Iron

IV iron is indicated in the following clinical scenarios:

Primary Indications

• Failure of oral iron therapy after at least 4 weeks of treatment, defined as hemoglobin failing to rise by ≥1 g/dL 1
• Intolerance to oral iron preparations despite trying alternative formulations (ferrous gluconate, fumarate, or liquid preparations) 4, 1
• Severe anemia with hemoglobin <9.0 g/dL requiring physician referral and consideration of rapid correction 1
• Advanced pregnancy (third trimester) when there is insufficient time for oral iron to adequately replenish maternal and fetal iron stores 5, 6

Secondary Indications

• Impaired iron absorption due to conditions such as celiac disease or post-bariatric surgery 6
• Ongoing blood loss where oral iron cannot keep pace with losses 6
• Clinical need for rapid and efficient treatment when time is limited before delivery 5

Preferred IV Iron Preparation

Ferric carboxymaltose (Injectafer) is the preferred agent based on clinical trial evidence in pregnancy and postpartum populations 1:

• Dosing: 15 mg/kg body weight up to maximum 750 mg per dose 1
• Administration: Two doses separated by at least 7 days, for cumulative dose up to 1,500 mg 1
• Infusion time: 15 minutes, significantly more convenient than older preparations 1

Alternative Preparations

• Iron sucrose (Venofer): Maximum 200 mg per dose, 10-minute infusion 1
• Iron dextran (Cosmofer): Can give total dose in single 6-hour infusion but carries 0.6-0.7% risk of serious reactions including anaphylaxis 1

Timing Considerations

Gestational age matters for IV iron decisions:

• IV iron is safe and effective in the second and third trimesters 7
• In the third trimester, IV iron is preferred when hemoglobin is <8 g/dL at any time, as oral iron has little expectation of delivering adequate iron to the fetus 7
• Avoid ferritin measurement within 4 weeks after IV iron infusion, as circulating iron interferes with the assay and produces falsely elevated results 2

Monitoring Response

After IV iron administration:

• Reassess hemoglobin at 2-4 weeks: Expected increase of ≥1 g/dL 1
• Once hemoglobin normalizes for gestational age, decrease to maintenance dose of 30 mg/day oral iron 1
• Recheck ferritin 4-8 weeks after initiating any iron therapy to determine if stores have been restored 2

Common Pitfalls to Avoid

• Do not rely on hemoglobin alone to diagnose iron deficiency—ferritin is the most specific indicator of depleted iron stores 2
• Do not assume compliance with oral iron—treatment failure is most commonly due to poor adherence 4
• Do not measure ferritin during inflammation or infection, as it is an acute phase reactant and may be falsely elevated, masking true iron deficiency 2
• Do not delay IV iron in severe anemia (<9.0 g/dL) or late pregnancy when oral iron is unlikely to be effective in time 1, 7

Safety Profile

• Anaphylactic reactions are extremely rare with non-dextran products, but close surveillance during administration is recommended for all IV iron products 5
• IV iron preparations with complex carbohydrate cores that bind elemental iron more tightly have excellent safety profiles 7
• Ferric carboxymaltose has been studied in well-controlled clinical trials in pregnancy and postpartum and should be preferred for safety reasons 5